Company: CNTB
Filing Date: 2025-09-10
Form Type: POS AM
Source: 0001193125-25-200186
Chunk: 69

Company: Connect Biopharma Holdings Ltd
Filing Date: 2025-09-10
Form: POS AM
Chunk 69
---
.                                                                    |

| • |     | Our IT Systems, or those of our CROs, manufacturers, other contractors, vendors, consultants or collaborators,                                                                                                                                           
 may fail or suffer system failures, security breaches or deficiencies in cybersecurity, which could result in a material disruption of our product development programs, compromise sensitive information related to our business or trigger contractual 
 and legal obligations.                                                                                                                                                                                                                                   |

| • |     | Our employees and independent contractors, including principal investigators, CROs, consultants and vendors,               
 may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. |

6

| • |     | We may engage in strategic transactions that could impact our liquidity, increase our expenses and present 
 significant distractions to our management.                                                                |

| • |     | Significant changes or developments in U.S. laws or policies, including changes in U.S. trade policies and                                                  
 tariffs and the reaction of other countries thereto, may have a material and adverse effect on our business, financial condition and results of operations. |

Risks Related to Intellectual Property

| • |     | Our success depends on our ability to obtain, maintain, protect and enforce our intellectual property and our 
 proprietary technologies.                                                                                     |

| • |     | If we fail to comply with our obligations under any license, collaboration or other agreements, or otherwise                                                                                                                                           
 experience disruptions to our business relationships with our collaborators or future licensors, we may be required to pay damages and could lose intellectual property rights that are necessary for developing and protecting our current and future 
 Product Candidates.                                                                                                                                                                                                                                    |

| • |     | If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent                                                                   
 protection, our ability to prevent our competitors and other third parties from commercializing Product Candidates similar or identical to ours would be adversely affected. |

| • |     | The patent protection and patent prosecution for our current or any future Product Candidates may be dependent 
 on third parties.                                                                                              |

| • |     | If we are not successful in obtaining patent term extensions for our current and future Product Candidates,                                                                                                                                       
 our business may be harmed, and the lack of effective enforcement of patent linkage and the absence of patent term extension and data and market exclusivity for Product Candidates approved by the NMPA could increase the risk of early generic 
 competition with our products in the PRC.                                                                                                                                                                                                         |

| • |     | Obtaining and maintaining our patent protection depends on compliance with various procedural